Search Prime Grants

2404776

Project Grant

Overview

Grant Description
SBIR Phase I: Gamma camera design studies for intraoperative imaging.

The broader impact and commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel capital medical imaging system enabling new three-dimensional (3D) image capture and analysis for real-time guidance of surgical cancer biopsy and resection procedures.

The system aims to significantly improve radio-guided surgical procedures with a novel means of rapidly and accurately detecting gamma-ray emitting radiotracers used to identify the location of lymph nodes (LN) and drainage of lymphatic fluids from tumors to be biopsied for determination of whether the primary cancers have spread.

The overall benefits include shorter durations and more accurate sentinel lymph node biopsy procedures.

If successful, the system represents a new standard of care versus current non-imaging technologies including Geiger pens, and targets a $3B initial opportunity for an initial target market of skin cancer accounting for 1.5M annual new US cases per year.

The system provides potential to impact other similar performed procedures used to assess suspected breast, pelvic and head and neck cancers.

This Small Business Innovation Research (SBIR) Phase I project will develop the company’s proprietary gamma ray radiation imager suitable for use for image guided tumor diagnostics.

The project will include individual and grouped characterization of the design parameters and their effect on diagnostic sensitivity for acquiring images, and whether convolutional mathematical approaches to iterative image reconstruction can reduce the time needed to produce the final image of a medical radiotracer.

The final objective is to determine the optimal collimation design parameters and image reconstruction techniques, followed by validation.

The end result will be to demonstrate proof-of-principle that the novel gamma imager can produce fast, high-resolution images adequate for radio-guided lymph node biopsy and resection surgeries.

The result will demonstrate superiority to current gamma camera approaches that utilize parallel-hole, pinhole, or coded-aperture collimation allowing them to produce either 1) low-resolution images rapidly or 2) high-resolution images slowly, but not the fast and high-resolution imaging needed for surgical guidance.

This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.

Subawards are not planned for this award.
Awardee
M3D
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Awarding / Funding Agency
Place of Performance
Ann Arbor, Michigan 48108-9649 United States
Geographic Scope
Single Zip Code
M3D was awarded Project Grant 2404776 worth $275,000 from National Science Foundation in September 2024 with work to be completed primarily in Ann Arbor Michigan United States. The grant has a duration of 1 year and was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships. The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.

SBIR Details

Research Type
SBIR Phase I
Title
SBIR Phase I: Gamma Camera Design Studies for Intraoperative Imaging
Abstract
The broader impact and commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel capital medical imaging system enabling new 3-Dimensional (3D) image capture and analysis for real-time guidance of surgical cancer biopsy and resection procedures. The system aims to significantly improve radio-guided surgical procedures with a novel means of rapidly and accurately detecting gamma-ray emitting radiotracers used to identify the location of lymph nodes (LN) and drainage of lymphatic fluids from tumors to be biopsied for determination of whether the primary cancers have spread. The overall benefits include shorter durations and more accurate sentinel lymph node biopsy procedures. If successful, the system represents a new standard of care versus current non-imaging technologies including Geiger pens, and targets a $3B initial opportunity for an initial target market of skin cancer accounting for 1.5M annual new US cases per year. The system provides potential to impact other similar performed procedures used to assess suspected breast, pelvic and head and neck cancers. This Small Business Innovation Research (SBIR) Phase I project will develop the company’s proprietary gamma ray radiation imager suitable for use for image guided tumor diagnostics. The project will include individual and grouped characterization of the design parameters and their effect on diagnostic sensitivity for acquiring images, and whether convolutional mathematical approaches to iterative image reconstruction can reduce the time needed to produce the final image of a medical radiotracer. The final objective is to determine the optimal collimation design parameters and image reconstruction techniques, followed by validation. The end result will be to demonstrate proof-of-principle that the novel gamma imager can produce fast, high-resolution images adequate for radio-guided lymph node biopsy and resection surgeries. The result will demonstrate superiority to current gamma camera approaches that utilize parallel-hole, pinhole, or coded-aperture collimation allowing them to produce either 1) low-resolution images rapidly or 2) high-resolution images slowly, but not the fast and high-resolution imaging needed for surgical guidance. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 23-515

Status
(Complete)

Last Modified 9/17/24

Period of Performance
9/1/24
Start Date
8/31/25
End Date
100% Complete

Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to 2404776

Additional Detail

Award ID FAIN
2404776
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
YVW7EGYWXGM6
Awardee CAGE
None
Performance District
MI-06
Senators
Debbie Stabenow
Gary Peters
Modified: 9/17/24